The Effect of Sulfonylureas on Lipids in T2DM

This article originally appeared here.
Review Explores Effect of Sulfonylureas on Lipids in T2DM
Review Explores Effect of Sulfonylureas on Lipids in T2DM

(HealthDay News) — For patients with type 2 diabetes mellitus (T2DM), sulfonylureas seem to increase levels of free fatty acids (FFA) and triglycerides (TG) and lower low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), according to a meta-analysis published online June 4 in the Journal of Evidence-Based Medicine.

Yue-hong Chen, M.D., from Sichuan University in Chengdu, China, and colleagues conducted a systematic literature review to examine the effects of second- and/or third-generation sulfonylureas on the level of lipids in patients with T2DM. Data were included from 52 randomized controlled trials.

The researchers found that sulfonylureas correlated with a statistically significant increase in the levels of FFA (standardized mean difference = 0.24) and TG (mean difference [MD] = 0.06), and correlated with decreases in HDL-C and LDL-C (MD = −0.07 and −0.11, respectively). The sulfonylureas had no effect on total cholesterol, ApoA1, and Apo B (MD = 0.01, 0.01, and −0.01, respectively). Sulfonylureas increased total cholesterol and LDL-C compared with metformin, increased total cholesterol and lowered HDL-C compared with glinides, and reduced total cholesterol, LDL-C, HDL-C, and increased triglycerides compared with thiazolidinediones.

"Sulfonylureas have a small effect on lipids, although they may statistically increase the level of FFA and TG, and decrease LDL-C and HDL-C," the authors write.

Abstract
Full Text (subscription or payment may be required)

Loading links....